Department of Surgery, Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Acta Oncol. 2023 Dec;62(12):1732-1741. doi: 10.1080/0284186X.2023.2259081. Epub 2023 Nov 25.
The implementation of current treatment modalities and their impact on nationwide gastric cancer outcomes remain poorly understood. Biological differences between females and males could impact survival. We aimed to analyze rates of gastric surgery, chemotherapy, and radiotherapy as well as changes in overall survival among gastric cancer patients diagnosed between 2000-2008 and 2009-2016, respectively, in Finland.
Data on gastric cancer patients were collected from national registries. Cox regression analysis and the Kaplan-Meier method were used to analyze differences in survival.
We identified 9223 histologically confirmed gastric cancer patients. The rate of gastric surgery decreased from 44% ( = 2282) to 34% ( = 1368; < 0.001). The proportion of gastric surgery patients who underwent preoperative oncological treatment increased from 0.5% ( = 12) to 16.2% ( = 222) between the calendar periods ( < 0.001) and stood at 30% in 2016. The median overall survival (OS) improved from 30 months [95% confidence interval (CI) 28-33] to 38 months (95%CI 33-42; = 0.006) and the period 2009-2016 independently associated with a lower risk of death [hazard ratio (HR) 0.78, 95%CI 0.70-0.87] among patients who underwent gastric surgery. Females exhibited a lower risk of death (HR 0.88, 95%CI 0.81-0.97) among patients who underwent gastric surgery.
Preoperative oncological treatment was gradually introduced into clinical practice and OS among gastric surgery patients improved. Moreover, female surgical patients exhibited a better survival than male patients.
目前治疗方式的实施情况及其对全国胃癌结局的影响仍知之甚少。男女之间的生物学差异可能会影响生存。我们旨在分析芬兰分别在 2000-2008 年和 2009-2016 年诊断的胃癌患者的胃切除术、化疗和放疗比率以及总生存率的变化。
从国家登记处收集了胃癌患者的数据。使用 Cox 回归分析和 Kaplan-Meier 方法分析生存差异。
我们确定了 9223 例组织学证实的胃癌患者。胃切除术的比例从 44%(=2282)降至 34%(=1368;<0.001)。接受术前肿瘤治疗的胃切除术患者比例从两个时期的 0.5%(=12)增至 16.2%(=222)(<0.001),并在 2016 年达到 30%。总生存(OS)中位数从 30 个月[95%置信区间(CI)28-33]提高至 38 个月(95%CI 33-42;=0.006),2009-2016 年期间与接受胃切除术的患者死亡风险降低独立相关[风险比(HR)0.78,95%CI 0.70-0.87]。接受胃切除术的女性患者死亡风险较低(HR 0.88,95%CI 0.81-0.97)。
术前肿瘤治疗逐渐引入临床实践,接受胃切除术的患者的 OS 得到改善。此外,女性手术患者的生存情况优于男性患者。